Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Boston Scientific emphasizes the importance of diversity in clinical trials to enhance patient outcomes. In a joint effort with Medtronic, the companies aim to increase representation among trial participants to reflect the diverse populations they serve. Laura Mauri, MD, from Medtronic, highlighted that inclusive representation is essential not only for addressing health inequities but also for understanding product efficacy across varied demographics. This strategic focus on diverse clinical trials aims to improve treatment effectiveness and outcomes for a broader patient base.
Summary not available.
Boston Scientific highlights challenges faced by transgender employees in the workplace, as illustrated by the experiences of Trevor Boylston, who transitioned a decade before joining the company. After encountering negative comments about his gender identity, Boylston advocated for inclusivity and understanding among coworkers. The press release features an event focused on the transgender community, aimed at fostering positive employment experiences and addressing workplace discrimination. It underscores the importance of supporting diverse identities in professional settings, particularly in light of ongoing societal changes.
Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on March 1, 2023. The event will feature a 40-minute question-and-answer session with key executives, Dan Brennan, Chief Financial Officer, and Lauren Tengler, Vice President of Investor Relations, at 8:00 a.m. EST. Interested parties can access a live webcast of the session through the Boston Scientific Investor Relations website, with a replay available one hour post-event. Boston Scientific is dedicated to transforming lives with innovative medical solutions and has been a leader in medical technology for over 40 years.
Boston Scientific emphasizes the importance of career strategies amidst the growing trend of work-life integration. As caregiving responsibilities, particularly among women, have come to the forefront during recent years, the company highlights the need for discussions surrounding career management. According to the CDC, two out of every three caregivers in the U.S. are women, who provide significant support for children and adults with various needs. The press release calls for a renewed focus on how individuals can take charge of their career paths in this evolving landscape.
Boston Scientific Corporation (NYSE: BSX) announced FDA 510(k) clearance for the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first system to monitor intrarenal pressure in real-time during ureteroscopy. Ureteroscopy is vital for treating kidney stones, affecting about 10% of people. The new system aims to reduce complications from elevated intrarenal pressure, which can lead to severe post-operative issues. Enhancements include improved image quality, updated control features, and streamlined integration with existing operating room systems. Limited market release in the U.S. will begin soon.
Boston Scientific generated net sales of $3.242 billion in Q4 2022, increasing by 3.7% year-over-year. The results reflect an 8.7% operational and 7.1% organic growth, despite a 200 basis point impact from Italian payback provisions. GAAP net income was $126 million or $0.09 EPS, lower than expected guidance. For 2022, total net sales reached $12.682 billion, a 6.7% growth, but GAAP net income fell to $642 million or $0.45 EPS. The company anticipates 5% to 7% net sales growth in 2023 and has announced acquisitions to expand its portfolio.
Boston Scientific Corporation (NYSE: BSX) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST in San Francisco, California. CEO Mike Mahoney will present alongside other key executives. Additionally, the company will host a conference call on February 1, 2023, at 8:00 a.m. EST, to discuss its fourth-quarter financial results for the period ending December 31, 2022. A news release will precede this call, providing financial highlights.
Boston Scientific Corporation (BSX) announced a partial offer to acquire up to 65% of Acotec Scientific Holdings Limited for HK$20 per share, totaling approximately US$523 million. Acotec specializes in innovative medical solutions, generating RMB 339 million in sales for the 12 months ending June 30, 2022, reflecting a 25% year-over-year growth. The acquisition aims to enhance Boston Scientific's presence in China and commercialize Acotec's products globally. While the expected impact on adjusted earnings per share is immaterial in 2023, the transaction's completion is subject to shareholder approval.
Boston Scientific has announced a definitive agreement to acquire Apollo Endosurgery for $10 per share, valuing the deal at approximately $615 million. This acquisition aims to enhance Boston Scientific's endoluminal surgery portfolio and expand its presence in the endobariatric market, a growing sector for weight management solutions. Apollo is projected to generate net sales of around $76 million in 2022, driven by its innovative endoscopic suturing systems. The transaction is expected to close in the first half of 2023, with minimal impact on adjusted earnings per share in 2023 but accretive thereafter.